Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Peking Union Medical College Hospital
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
67High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07000344CT.gov A Study of Apatinib Combined With Letrozole With or Without Fluzoparib in Estrogen Receptor-Positive, Platinum-Sensitive Recurrent Ovarian Cancer Previously Treated With First-Line PARP Inhibitor | — | Terminated | — | — | — |
NCT07033819CT.gov Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib | — | Recruiting | — | — | — |
NCT06769425CT.gov HS-10502 Combination Treatment in Patients With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06188455CT.gov Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer | — | Not Yet Recruiting | — | — | — |
NCT06161272CT.gov Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi | — | Unknown | — | — | — |
NCT06102707CT.gov The Efficacy and Safety of Fluzopril Combined With Apatinib in Maintenance Treatment of Platinum Resistant Recurrent Ovarian Cancer Patients | — | Not Yet Recruiting | — | — | — |
NCT06081595CT.gov Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment | — | Not Yet Recruiting | — | — | — |
NCT05597527CT.gov Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer | — | Unknown | — | — | — |
NCT05479487CT.gov Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment | — | Not Yet Recruiting | — | — | — |
NCT04517357CT.gov A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients | — | Completed | — | — | — |
Show 14 more trialsShow fewer
NCT04590625CT.gov Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian Cancer | — | Unknown | — | — | — |
NCT04229615CT.gov A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy | — | Unknown | — | — | — |
NCT04383977CT.gov Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian Cancer | — | Unknown | — | — | — |
NCT04068974CT.gov Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer | — | Unknown | — | — | — |
NCT03942068CT.gov Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer | — | Unknown | — | — | — |
NCT04000295CT.gov Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer | — | Unknown | — | — | — |
NCT03587129CT.gov Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer | — | Terminated | — | — | — |
NCT03547375CT.gov Clinical Study of Apatinib in the Treatment of Advanced Ovarian Cancer After the Failure of Standard Chemotherapy | — | Unknown | — | — | — |
NCT04348032CT.gov Apatinib Combined With PLD vs PLD for Platinum-resistant Recurrent Ovarian Cancer | — | Unknown | — | — | — |
NCT03298074CT.gov Apatinib Plus Etoposide Versus Etoposide Alone for Platinum-resistant Recurrent Ovarian Cancer | — | Unknown | — | — | — |
NCT03393507CT.gov A Study of Apatinib Treatment in for Advanced Ovarian Cancer | — | Unknown | — | — | — |
NCT03075462CT.gov A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients | — | Completed | — | — | — |
NCT03384511CT.gov The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. | — | Completed | — | — | — |
NCT02867956CT.gov Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rivoceranib (this asset) | Peking Union Medical College Hospital | Approved | BB · 64 |
| Tisotumab Vedotin | Seagen Inc. | P2 | BB |
| TIL | Inge Marie Svane | P2 | BB |
| Olaparib | Shandong University | P4 | BB |
| Cis-Diamminedichloroplatinum Ii | Kalinski, Pawel, MD, PhD | P3 | BB |
| Adriamycin | Genmab | P3 | BB |
| Carboplatin | Fudan University | P4 | BB |
| OTL-38 | On Target Laboratories, LLC | P4 | BB |
| Irinotecan | ARCAGY/ GINECO GROUP | P4 | BB |
+42 more in the Ovarian Cancer cohort
Other indications for Rivoceranib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Gastric Cancer | — | P4 | BBB · 73 |
| Peripheral T-Cell Lymphoma, Not Otherwise Specified | — | P4 | BBB · 72 |
| Cancer | — | P4 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Rivoceranib in Ovarian Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/rivoceranib-ovarian-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →